• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT LABORATORIES ARCHITECT CA 19-9XR CANCER ANTIGEN 19-9

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT LABORATORIES ARCHITECT CA 19-9XR CANCER ANTIGEN 19-9 Back to Search Results
Catalog Number 02K91-32
Device Problem Low Test Results (2458)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 07/28/2017
Event Type  malfunction  
Manufacturer Narrative
A review of complaint tracking and trending metrics was performed and identified no adverse trends in conjunction with the complaint issue currently under evaluation. No non-conformances or deviations associated with the affected reagent lot were identified. An in-house retained reagent kit of architect ca 19-9xr reagent, lot number 73036m800, was tested in an accuracy performance setup. Results from this testing did not implicate that the accuracy performance of the lot is negatively impacted. All acceptance criteria met specifications. No returns were made available from the customer site. The architect ca 19-9xr assay package insert contains information to address the current customer issue. Based on the results of this evaluation and the information from the customer site, no systemic issue or product deficiency was identified. This report is being filed on an international product, list number 02k91-32, that has a similar product distributed in the us, list number 02k91-29. Pt identifier: sid (b)(6). This issue was previously reported under mdr number 3002809144-2017-00114 under a different suspect device manufacturer.
 
Event Description
The customer reports the following results being generated with the architect ca 19-9xr assay for a patient diagnosed with pancreatic cancer and being monitored with samples tested on an architect i2000sr analyzer (the following results are from the same patient tested on (b)(6) 2017): sid (b)(6): 1. 81 u/ml. Sid (b)(6): 79. 96 u/ml. Sid (b)(6): 61. 54 u/ml. Controls have remained within specifications. No suspect results have been reported from the lab. There is no impact to patient management reported.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameARCHITECT CA 19-9XR
Type of DeviceCANCER ANTIGEN 19-9
Manufacturer (Section D)
ABBOTT LABORATORIES
100 abbott park road
abbott park IL 60064 3500
Manufacturer (Section G)
ABBOTT LABORATORIES
100 abbott park road
abbott park IL 60064 3500
Manufacturer Contact
noemi romero-kondos, rn bsn
100 abbott park road
dept. 09b9, lccp1-3
abbott park, IL 60064-3537
224667-512
MDR Report Key7043482
MDR Text Key93214540
Report Number1415939-2017-00205
Device Sequence Number1
Product Code NIG
Combination Product (y/n)N
Reporter Country CodeJA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Reporter Occupation
Type of Report Initial
Report Date 11/17/2017
1 Device was Involved in the Event
0 Patients were Involved in the Event:
Date FDA Received11/17/2017
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator
Device Expiration Date01/03/2018
Device Catalogue Number02K91-32
Device Lot Number73036M800
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received11/16/2017
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured02/01/2017
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage

-
-